---
title: "Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295674999.md"
description: "Liquidia exceeded Wall Street's expectations for the second quarter with strong sales of its lung disease treatment, Yutrepia, experiencing double-digit growth. The company's performance as an IBD 50 stock was highlighted, showcasing its ability to surpass sales projections despite competition from United Therapeutics. This success underscores Liquidia's promising position in the market."
datetime: "2026-08-12T13:33:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295674999.md)
  - [en](https://longbridge.com/en/news/295674999.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295674999.md)
---

# Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry

Liquidia exceeded Wall Street's expectations for the second quarter with strong sales of its lung disease treatment, Yutrepia, experiencing double-digit growth. The company's performance as an IBD 50 stock was highlighted, showcasing its ability to surpass sales projections despite competition from United Therapeutics. This success underscores Liquidia's promising position in the market.

### Related Stocks

- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)
- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares](https://longbridge.com/en/news/295639080.md)
- [United Therapeutics CEO Chairperson Martine Rothblatt disposes of 9,500 shares worth $5.03 million](https://longbridge.com/en/news/295448656.md)
- [LQDA: Q2 2026 net income reached $74.7M as YUTREPIA sales and market share accelerated](https://longbridge.com/en/news/295651428.md)
- [LQDA: YUTREPIA's accelerating growth and profitability position it to exceed $1B in net revenue by 2027](https://longbridge.com/en/news/295680901.md)
- [Analyst Sees Yutrepia’s Strong Commercial Trajectory and Liquidia Pipeline Supporting Buy Rating and Billion-Dollar Sales Outlook](https://longbridge.com/en/news/295699064.md)